Wegovy Outperforms Zepbound and Tirzepatide in Reducing Heart Risks
TL;DR Summary
A real-world study shows that Novo Nordisk's Wegovy significantly outperforms Eli Lilly's Zepbound, reducing serious heart issues like stroke by over 50%.
- Novo's Wegovy beats Lilly’s Zepbound in real-world study for heart diseases Seeking Alpha
- Weight loss drugs can halve heart patients’ risk of early death, study finds The Guardian
- Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease PR Newswire
- Weight loss jabs could keep heart failure patients out of hospital The Independent
- Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
73%
83 → 22 words
Want the full story? Read the original article
Read on Seeking Alpha